HealthEquity, Inc. (NASDAQ:HQY – Free Report) – Research analysts at Zacks Research cut their Q3 2024 earnings per share estimates for HealthEquity in a research note issued on Wednesday, November 1st. Zacks Research analyst D. Dey now anticipates that the company will post earnings per share of $0.30 for the quarter, down from their previous estimate of $0.31. The consensus estimate for HealthEquity’s current full-year earnings is $1.35 per share. Zacks Research also issued estimates for HealthEquity’s Q1 2025 earnings at $0.32 EPS, Q2 2025 earnings at $0.37 EPS, Q3 2025 earnings at $0.34 EPS, FY2025 earnings at $1.43 EPS, Q1 2026 earnings at $0.44 EPS and Q3 2026 earnings at $0.40 EPS.
A number of other equities research analysts also recently commented on HQY. Robert W. Baird upgraded HealthEquity from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $79.00 to $87.00 in a research report on Thursday, September 21st. Royal Bank of Canada lifted their price objective on HealthEquity from $75.00 to $77.00 and gave the company an “outperform” rating in a research note on Wednesday, September 6th. Deutsche Bank Aktiengesellschaft lifted their price objective on HealthEquity from $71.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, September 7th. Barrington Research boosted their target price on HealthEquity from $80.00 to $85.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 6th. Finally, StockNews.com assumed coverage on HealthEquity in a research note on Thursday, October 5th. They set a “hold” rating for the company. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, HealthEquity has an average rating of “Moderate Buy” and an average target price of $84.14.
HealthEquity Stock Performance
Shares of HealthEquity stock opened at $64.14 on Friday. HealthEquity has a one year low of $48.86 and a one year high of $78.01. The company has a market cap of $5.49 billion, a price-to-earnings ratio of 427.60, a PEG ratio of 1.88 and a beta of 0.77. The company has a debt-to-equity ratio of 0.45, a quick ratio of 4.09 and a current ratio of 4.09. The business’s 50 day moving average price is $71.38 and its 200 day moving average price is $64.86.
HealthEquity (NASDAQ:HQY – Get Free Report) last released its earnings results on Tuesday, September 5th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.06. HealthEquity had a return on equity of 5.08% and a net margin of 1.37%. The business had revenue of $243.55 million for the quarter, compared to the consensus estimate of $238.89 million.
Insider Activity at HealthEquity
In related news, insider Tyson D. Murdock sold 2,844 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $71.35, for a total value of $202,919.40. Following the completion of the transaction, the insider now directly owns 70,389 shares of the company’s stock, valued at approximately $5,022,255.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other HealthEquity news, CEO Jon Kessler sold 46,818 shares of the firm’s stock in a transaction on Wednesday, September 27th. The stock was sold at an average price of $75.03, for a total transaction of $3,512,754.54. Following the completion of the transaction, the chief executive officer now owns 213,991 shares of the company’s stock, valued at $16,055,744.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Tyson D. Murdock sold 2,844 shares of the firm’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $71.35, for a total value of $202,919.40. Following the sale, the insider now owns 70,389 shares in the company, valued at approximately $5,022,255.15. The disclosure for this sale can be found here. Insiders sold 62,144 shares of company stock valued at $4,622,991 in the last ninety days. Corporate insiders own 2.70% of the company’s stock.
Institutional Investors Weigh In On HealthEquity
Several hedge funds have recently made changes to their positions in HQY. Wasatch Advisors LP lifted its stake in shares of HealthEquity by 34.6% during the first quarter. Wasatch Advisors LP now owns 7,712,589 shares of the company’s stock worth $452,806,000 after purchasing an additional 1,980,668 shares in the last quarter. Norges Bank purchased a new stake in shares of HealthEquity during the fourth quarter worth about $34,071,000. Clearbridge Investments LLC increased its position in shares of HealthEquity by 39.9% during the first quarter. Clearbridge Investments LLC now owns 1,592,430 shares of the company’s stock worth $93,492,000 after acquiring an additional 454,245 shares during the last quarter. BlackRock Inc. increased its holdings in HealthEquity by 4.0% in the first quarter. BlackRock Inc. now owns 9,423,008 shares of the company’s stock valued at $635,488,000 after buying an additional 358,743 shares during the last quarter. Finally, Sei Investments Co. increased its holdings in HealthEquity by 117.3% in the first quarter. Sei Investments Co. now owns 617,545 shares of the company’s stock valued at $36,256,000 after buying an additional 333,303 shares during the last quarter. Institutional investors and hedge funds own 98.46% of the company’s stock.
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
- Five stocks we like better than HealthEquity
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Shocking uranium play that hedge funds kept hidden
- How to Invest in Blue Chip Stocks
- Dependable dividends: Why utility stocks are on fire
- How to Invest in Solar Energy
- Realtor verdict, poor revenue guidance send Zillow stock plunging
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.